Business
Enzolytics Highlights Its Comprehensive PCT Patent Applications Covering Discovered Conserved Target Epitopes on the SARS-CoV-2 and HIV Viruses
Enzolytics Highlights Its Comprehensive PCT Patent Applications Covering Discovered Conserved Target Epitopes on the SARS-CoV-2 and HIV Viruses.
About this update from Enzolytics Inc.
[{"type":"text","content":"COLLEGE STATION, TX / ACCESSWIRE / March 25, 2022 / Enzolytics, Inc. (OTC PINK:ENZC) (https://enzolytics.com/.)In submissions under the Patent Cooperation Treaty (PCT), Enzolytics, Inc. has pending international patent applications covering the use of any of its discovered numerous conserved Coronavirus epitopes or conserved HIV epitopes in the production of monoclonal antibodies, the production of vaccines or use in diagnostic tests for detecting the viruses in patients.The applications are pending as Patent Cooperation Treaty (PCT) applications which allow the Company to prosecute the applications both in the U.S. and in all PCT member countries. The applications identify and claim the conserved, immutable sites on the SARS-CoV-2 virus and HIV virus that have been identified by the Company through its Artificial Intelligence (AI) technology. These applications, and their significance, are based on the following findings by the Company.By using computer analysis (AI), the Company has analyzed over 2 Million different isolates of the Coronavirus. From that analysis, the Company identified 19 conserved, immutable sites (epitopes) on the virus. The 19 conserved sequences identified on the isolates analyzed have been identified on the basis that they are 98.71% to 99.29% conserved over the entirety of the over 2 Million CoronaVirus isolates which have been analyzed by the Company using AI.Additionally, the Company has analyzed over 100,000 HIV isolates using AI and has identified 9 conserved sites, some with over 98% conserved sequences.In its PCT Patent Applications, the Company has claimed its discoveries including the use of these identified conserved epitopes for (1) producing a therapeutic monoclonal antibody to treat HIV or the CoronaVirus, (2) producing a vaccine against HIV or the CoronaVirus, or (3) for use in any diagnostics to identify whether a person has HIV or the CoronaVirus.The Company considers these filings significant because:For a monoclonal antibody to be effective (that is to be fully capable of neutralizing a virus), it must target an immutable site on the virus. Otherwise, a virus mutation will render the therapeutic ineffective.The Company has analyzed over 2 Million Coronavirus isolates and over 100,000 HIV isolates and have identified 19 conserved sites (98 to 99% conserved) on the Coronavirus and 9 conse...